Literature DB >> 24247157

Nonmydriatic ultra-wide-field scanning laser ophthalmoscopy (Optomap) versus two-field fundus photography in diabetic retinopathy.

Raffael Liegl1, Kristine Liegl, Lala Ceklic, Christos Haritoglou, Anselm Kampik, Michael W Ulbig, Marcus Kernt, Aljoscha S Neubauer.   

Abstract

The purpose of this study was to investigate the diagnostic properties of a 2-laser wavelength nonmydriatic 200° ultra-wide-field scanning laser ophthalmoscope (SLO) versus mydriatic 2-field 45° color fundus photography (EURODIAB standard) for assessing diabetic retinopathy (DR). A total of 143 consecutive eyes of patients with different levels of DR were graded regarding DR level and macular edema based on 2-field color photographs or 1 Optomap Panoramic 200 SLO image. All SLO images were nonmydriatic and all photographs mydriatic. Grading was performed masked to patient and clinical data. Based on photography, 20 eyes had no DR, 44 had mild, 18 moderate and 42 severe nonproliferative DR, and 19 eyes had proliferative DR. Overall correlation for grading DR level compared to Optomap SLO was moderate with kappa 0.54 (p < 0.001), fair-to-moderate in macular edema grading with kappa 0.39 (p < 0.001), and substantial for grading clinically significant macular edema (kappa 0.77). The wide-field SLO offers a wider field of view and can potentially better differentiate lesions by applying the 2 laser wavelengths. However, these advantages over 2-field fundus photography need to be confirmed in further studies.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24247157     DOI: 10.1159/000355092

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  2 in total

Review 1.  Diabetic retinopathy - ocular complications of diabetes mellitus.

Authors:  Martin M Nentwich; Michael W Ulbig
Journal:  World J Diabetes       Date:  2015-04-15

Review 2.  The English National Screening Programme for diabetic retinopathy 2003-2016.

Authors:  Peter H Scanlon
Journal:  Acta Diabetol       Date:  2017-02-22       Impact factor: 4.280

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.